TB500: Community Protocols & Reports
Aggregated community experiences, protocols, and stacking patterns
Community-Sourced Information
The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.
For peer-reviewed dosing protocols, see the clinical dosing guide.
Browse community protocols for all 130 peptides →
📌TL;DR
- •4 community protocols documented
- •Evidence level: Structured Community Data
- •Based on 120 community reports
- •3 stacking patterns reported
Clinical vs. Community Protocol Differences
How community-reported protocols differ from clinical research protocols.
| Aspect | Clinical Approach | Community Approach | Significance |
|---|---|---|---|
| Dosing Approach | Clinical trials (dermal wounds, corneal injury) used specific weight-based or fixed doses of thymosin beta-4, with RGN-259 ophthalmic solution at 0.1% concentration. Veterinary use (equine) involved 10 mg IM injections. | Community uses fixed doses of 2-10 mg per injection regardless of body weight, with a loading/maintenance structure that is not reflected in published research. | high The loading + maintenance paradigm is entirely community-derived. Clinical trials used consistent dosing throughout the study period. |
| Administration Route | Published studies used intraperitoneal injection (rodent), intramuscular injection (equine), and topical/ophthalmic (human). No subcutaneous injection studies in humans. | Community overwhelmingly uses subcutaneous injection. Some users inject near injury sites, while others use abdominal SubQ for systemic distribution. | high SubQ injection is a community adaptation. The pharmacokinetics of SubQ TB-500 in humans have not been characterized in published research. |
| Molecular Form | Clinical trials used full-length Thymosin Beta-4 (43 amino acids) or RGN-259 formulations. Academic research uses the full Tβ4 protein. | Community uses TB-500, a synthetic fragment typically containing a 7-amino acid active region of Thymosin Beta-4. TB-500 and full-length Tβ4 are often used interchangeably in discussions despite being different molecules. | high TB-500 (the fragment) and Thymosin Beta-4 (the full protein) are distinct molecules. Published research findings on Tβ4 may not directly apply to the TB-500 fragment used by the community. |
Compare these community approaches with published research findings.
Community Protocols
Loading + Maintenance Protocol
Popular- Route
- Subcutaneous
- Dose
- 4-8 mg/week (loading), 2-4 mg/week (maintenance)
- Frequency
- 2-3 injections per week
- Duration
- 4-6 weeks loading, then ongoing maintenance
Most commonly reported protocol; loading phase of 6-8 mg/week split into 2-3 injections, then tapering to 2-4 mg every 1-2 weeks
Standard Recovery Protocol
Popular- Route
- Subcutaneous
- Dose
- 2-5 mg
- Frequency
- Twice weekly
- Duration
- 4-8 weeks
Used for general injury recovery; fixed twice-weekly dosing without a distinct loading phase
Low-Dose Healing Protocol
Common- Route
- Subcutaneous
- Dose
- 2 mg
- Frequency
- Twice weekly
- Duration
- 4-6 weeks
Conservative approach for minor injuries and joint discomfort; some users report good results at lower doses
Aggressive Injury Protocol
Niche- Route
- Subcutaneous
- Dose
- 5-10 mg
- Frequency
- 2-3 times weekly
- Duration
- 4-8 weeks
Used for severe injuries or post-surgical recovery; higher doses than most community members use
Stacking Patterns
TB-500 + BPC-157 Healing Stack
PopularThe most popular healing combination; TB-500 for systemic tissue repair and anti-inflammatory effects, BPC-157 for localized healing and angiogenesis
TB-500 + GHK-Cu Tissue Repair Stack
CommonCombines TB-500 systemic healing with GHK-Cu collagen remodeling and skin/tissue repair for comprehensive recovery
TB-500 + BPC-157 + GH Secretagogue Stack
NicheFull recovery stack adding GH stimulation to the healing peptide combination for enhanced tissue regeneration
Check stack compatibility and review potential side effects before combining peptides.
Unlock community dosing protocols and stacking combos
See the exact doses, routes, and schedules 120+ self-experimenters report. Free with email.
150+ peptide profiles · 30+ comparisons · 18 research tools
Sources
- Reddit r/Peptides|TB-500 experience reports and protocol discussions(accessed 2026-02-16)
- Reddit r/PeptideResearch|TB-500 dosing and injury recovery threads(accessed 2026-02-16)
- Swolverine|TB-500 Dosage Guide (loading and maintenance protocols)(accessed 2026-02-16)
- Revolution Health|TB-500 Peptide Therapy for Healing and Tissue Repair(accessed 2026-02-16)
- Wittmer Rejuvenation Clinic|TB-500 Treatment Plan for Injury Recovery(accessed 2026-02-16)
- Innerbody|TB4 and TB-500 Peptide Therapy (2026 guide)(accessed 2026-02-16)
- Peptides.org|TB-500 Reviews, Clinical Trials, and Safety(accessed 2026-02-16)
Community Evidence Overview#
This page presents aggregated community protocols and anecdotal reports for TB-500 (Thymosin Beta-4). The information below is gathered from peptide research forums, Reddit communities, and self-experimenter reports. This is not clinical evidence and should not be used as medical guidance.
TB-500 is one of the most widely discussed healing peptides in online communities, often used alongside BPC-157 for injury recovery. Community interest stems from preclinical and veterinary research showing tissue repair, anti-inflammatory, and cardioprotective effects. However, human clinical trial data is limited to the full-length Thymosin Beta-4 protein, not the TB-500 fragment commonly used by the community.
Understanding Protocol Divergence#
Full Protein vs Fragment#
A critical distinction often overlooked in community discussions is that TB-500 is not the same molecule as Thymosin Beta-4 (Tβ4). Published clinical trials (wound healing, corneal repair, cardiac ischemia) used the full 43-amino acid Tβ4 protein. TB-500 is a synthetic fragment typically containing a 7-amino acid active sequence. While the active region is shared, the pharmacokinetic properties, tissue distribution, and biological activity may differ significantly between the full protein and the fragment.
Loading Phase Paradigm#
The community-standard loading/maintenance protocol (high doses for 4-6 weeks, then reduced maintenance doses) has no basis in published research. Clinical trials used consistent dosing throughout the study period. The loading phase concept appears to have originated from equine veterinary practices and was adopted by the peptide community.
Route of Administration#
Published research uses intraperitoneal injection (rodents), intramuscular injection (horses), or topical/ophthalmic application (humans). The community's subcutaneous injection approach is an adaptation that has not been validated in pharmacokinetic studies.
Commonly Reported Outcomes#
Community members frequently report the following when using TB-500:
- Onset of effects: Most users report noticing improvements within 2-3 weeks, with significant progress by weeks 4-6
- Tendon and ligament injuries: Among the most commonly reported use cases, with users describing improved recovery from chronic tendinopathies
- Joint mobility: Users frequently report reduced stiffness and improved range of motion
- Post-surgical recovery: Some users report accelerated healing following orthopedic surgeries
- Hair growth: A secondary reported benefit, with some users noting increased hair thickness
Important Caveats#
- These are self-reported outcomes without controls, blinding, or objective measurement
- The TB-500 fragment used by the community differs from the Tβ4 used in clinical research
- Placebo effect, natural healing timelines, and concurrent treatments confound interpretation
- Product quality and actual peptide content vary significantly between vendors
- Long-term safety data for TB-500 in humans is not available
Reconstitution and Storage Practices#
Community reconstitution practices for TB-500:
- Reconstitution: 1-2 mL bacteriostatic water per 5 mg vial
- Storage: Reconstituted solution refrigerated at 2-8 degrees C
- Shelf life: Most users report using reconstituted TB-500 within 3-4 weeks
- Injection volume: Typically 0.25-0.5 mL per injection depending on concentration
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles · 30+ comparisons · 18 research tools
Frequently Asked Questions About TB500
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.